Vigene Biosciences, a leading provider of viral vector products and services used in gene therapy, has completed a substantial growth capital financing transaction. The investment was made by Signet Healthcare Partners, a New York-based growth equity firm specializing in healthcare investments.
Shulman Rogers’ Business and Financial Services Department represented Vigene in the transaction, drafting and negotiating the offering documents and providing counsel on business implications.
The growth capital will be used to support Vigene’s expansion into a new facility to support the growing demand for viral vector and plasmid production in the rapidly expanding fields of cell and gene therapy. Construction of the new facility, located in Rockville, Maryland, is set to be completed mid-2019. More details on Vigene’s expansion can be found here.
Stay up to date with all the latest news and events.
